Cover Story
NCI Director's Report
By Alexandria Carolan
As the likelihood of a flat budget increases for the 2024 fiscal year, NCI will have difficulty maintaining its current programs, the institute’s new director Kimryn Rathmell said in her inaugural NCI director’s report to members of the National Cancer Advisory Board Feb. 8.
In Brief
Drugs & Targets
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Tumors are able to form with no DNA mutations, fly study shows
- From clinician scientist to nonprofit CEO